Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gniadecki

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2022
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasisJ J Wu, A Kavanaugh, M G Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 21, 2017
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasisS H Omland, A Habicht, P Damsbo, et al.
The British Journal of Dermatology|August 19, 2014
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgarisR Gniadecki, B Bang, L E Bryld, et al.
The British Journal of Dermatology|August 2, 2016
Ubiquitin-specific peptidase 2 as a potential link between microRNA-125b and psoriasisT Wei, L Folkersen, E Biskup, et al.
The British Journal of Dermatology|November 29, 2019
Predicting the long-term outcomes of biologics in patients with psoriasis using machine learningS Emam, A X Du, P Surmanowicz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 17, 2009
Efalizumab for severe refractory atopic eczema: retrospective study on 11 casesK Ibler, T N Dam, R Gniadecki, et al.
The British Journal of Dermatology|September 16, 2021
Transcriptomic changes during stage progression of mycosis fungoidesM Z X Xiao, D Hennessey, A Iyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 14, 2015
Imaging of cutaneous T-cell lymphomas by optical coherence tomography - a case series studyH C Ring, A A Hussain, G B Jemec, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 9, 2017
Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registryA Egeberg, L Iversen, R Gniadecki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2018
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasisR Gniadecki, C L Leonardi, K B Gordon, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2022
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasisJ J Wu, A Kavanaugh, M G Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 21, 2017
A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasisS H Omland, A Habicht, P Damsbo, et al.
The British Journal of Dermatology|August 19, 2014
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgarisR Gniadecki, B Bang, L E Bryld, et al.
The British Journal of Dermatology|August 2, 2016
Ubiquitin-specific peptidase 2 as a potential link between microRNA-125b and psoriasisT Wei, L Folkersen, E Biskup, et al.
The British Journal of Dermatology|November 29, 2019
Predicting the long-term outcomes of biologics in patients with psoriasis using machine learningS Emam, A X Du, P Surmanowicz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 17, 2009
Efalizumab for severe refractory atopic eczema: retrospective study on 11 casesK Ibler, T N Dam, R Gniadecki, et al.
The British Journal of Dermatology|September 16, 2021
Transcriptomic changes during stage progression of mycosis fungoidesM Z X Xiao, D Hennessey, A Iyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 14, 2015
Imaging of cutaneous T-cell lymphomas by optical coherence tomography - a case series studyH C Ring, A A Hussain, G B Jemec, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 9, 2017
Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registryA Egeberg, L Iversen, R Gniadecki, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2018
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasisR Gniadecki, C L Leonardi, K B Gordon, et al.
Pageof 10